USP30 and Parkinson disease: MTX115325, a CNS-penetrant USP30 inhibitor with oral bioavailability, prevented dopaminergic neuron loss in α-synuclein Parkinson’s disease models, underscoring its therapeutic promise (Fang et al., 2023).